GPCR Key Statistics, Chart & Performance
The current stock price of GPCR is 84.33 USD. In the past month the price increased by 30.14%. In the past year, price increased by 211.64%.
GPCR Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to GPCR. When comparing the yearly performance of all stocks, GPCR is one of the better performing stocks in the market, outperforming 99.11% of all stocks.
GPCR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GPCR. No worries on liquidiy or solvency for GPCR as it has an excellent financial health rating, but there are worries on the profitability.
GPCR Financial Highlights
Over the last trailing twelve months GPCR reported a non-GAAP Earnings per Share(EPS) of -2.95. The EPS decreased by -24.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.32% | ||
| ROE | -27.36% | ||
| Debt/Equity | 0 |
GPCR Forecast & Estimates
20 analysts have analysed GPCR and the average price target is 94.31 USD. This implies a price increase of 11.84% is expected in the next year compared to the current price of 84.33.
GPCR Ownership
GPCR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.81 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 21.05 | 526.55B | ||
| MRK | MERCK & CO. INC. | 12.6 | 275.53B | ||
| PFE | PFIZER INC | 7.99 | 145.44B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.69 | 116.08B | ||
| ZTS | ZOETIS INC | 19.85 | 55.46B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.78 | 23.21B | ||
| VTRS | VIATRIS INC | 5.64 | 15.15B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.46 | 12.14B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.92B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.36B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.26B |
Related stock screener links
About GPCR
Company Profile
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company is headquartered in South San Francisco, California and currently employs 218 full-time employees. The company went IPO on 2023-02-03. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. The company is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. The company is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Company Info
STRUCTURE THERAPEUTICS INC
601 Gateway Blvd Suite 900
South San Francisco CALIFORNIA US
Employees: 218
Phone: 16504571978
STRUCTURE THERAPEUTICS INC / GPCR FAQ
What does STRUCTURE THERAPEUTICS INC do?
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company is headquartered in South San Francisco, California and currently employs 218 full-time employees. The company went IPO on 2023-02-03. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. The company is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. The company is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
What is the stock price of STRUCTURE THERAPEUTICS INC today?
The current stock price of GPCR is 84.33 USD. The price increased by 8.23% in the last trading session.
Does STRUCTURE THERAPEUTICS INC pay dividends?
GPCR does not pay a dividend.
What is the ChartMill rating of STRUCTURE THERAPEUTICS INC stock?
GPCR has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for STRUCTURE THERAPEUTICS INC?
STRUCTURE THERAPEUTICS INC (GPCR) operates in the Health Care sector and the Pharmaceuticals industry.
What is the outstanding short interest for STRUCTURE THERAPEUTICS INC?
The outstanding short interest for STRUCTURE THERAPEUTICS INC (GPCR) is 25.37% of its float.